1Bouchoucha M, Uzzan B, Cohen R. Metformin and di- gestive disorders[J]. Diabetes Metab, 2011,37 (2) : 90-95.
2Mawe GM,Coates MD, Moses PL. Intestinal serotonin signalling in irritable bowel syndrome [J]. Aliment Pharmacol Ther,2006,23(8) : 1067-1076.
3Cubeddu LX,Bonisch H, Gothert M, et al. Effects of metformin on intestinal 5-hydroxytryptamine (5-HT) release and on 5-HT3 receptors[J]. Naunyn Schmiede- bergs Arch Pharmacol, 2000,361 ( 1 ) : 85-91.
4Gershon MD,Tack J. The serotonin signaling system: from basic understanding to drug development for functional GI disorders [J]. Gastroenterology, 2007, 132:397-414.
5Bellini M,Rappelli L,Blandizzi C, et al. Platelet sero- tonint transporter in patients with diarrhea predomi- nant irritable bowel syndrome both before and after treatment with alosetron [J]. Am J Gastroenterol, 2003,98(12) : 2705-2711.
6Atkinson W, Lockhart S,Whorwell PJ, et al. Altered 5- hydroxytryptamine signaling in patients with constipa- tion and diarrhea predominant irritable bowel syndrome [J]. Gastroenterology, 2006,130 ( 1 ) 34-43.
7Frost M, Andersen T, Gossiel F, et ai. Levels of seroto- nin,sclerostin, bone turnover markers as well as bone density and microarchiteeture in patients with high- bone-mass phenotype due to a mutation in LrpS[J]. J Bone Miner Res,2011,26(8) : 1721-1728.
